Thursday, August 15, 2013
New partnerships and release of Phase
III data highlight a flurry of activity this summer around the autoimmune
Now, emerging research suggests companies developing inhibitors of IL-17A
signaling have both a repurposing opportunity and a new safety concern to
Problems with plaque
The Swedish-U.S. researchers wanted
to know how signaling between transforming growth factor β1 (TGFB1)
and mother against decapentaplegic homolog 7 (MADH7;
affected subpopulations of T cells in atherosclerosis, but they discovered a
role for IL-17A instead.
Moving along IL-17
In addition to monitoring the
cardiovascular health of patients receiving IL-17 inhibitors, the Swedish-U.S.
team wants to use its findings to develop therapies that could stabilize
atherosclerotic plaques and thus reduce the risk of cardiovascular events in
patients who have severe atherosclerosis.
Haas, M.J. SciBX 6(31); doi:10.1038/scibx.2013.814
Published online Aug. 15, 2013
1. Chung, A.S. et al.
Nat. Med.; published online Aug. 4, 2013; doi:10.1038/nm.3291
Contact: Napoleone Ferrara, University of California San Diego,
La Jolla, Calif.
2. Gisterå, A. et al.
Sci. Transl. Med.; published online July 31, 2013;
Contact: Göran K. Hansson, Karolinska Institute, Stockholm, Sweden
Contact: Richard A. Flavell, Yale University School of Medicine, New
3. Fridman, W.H. et al.
Nat. Rev. Cancer 12, 298-306 (2012)
AND INSTITUTIONS MENTIONED
Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan
Genentech Inc., South San Francisco, Calif.
Howard Hughes Medical Institute,
Chevy Chase, Md.
Karolinska Institute, Stockholm, Sweden
NovImmune S.A., Plan-les-Ouates, Switzerland
Roche, (SIX:ROG; OTCQX: RHHBY), Basel, Switzerland
Umeå University, Umeå, Sweden
University of California,San Diego, Calif.
Yale School of Medicine, New Haven, Conn.